Business & Regulation

What makes pharma so good at rebranding?

Can the USA boost its manufacturing capacity for critical drugs?

Pfizer is supporting homelearners amid the COVID-19 pandemic.

From patient recruitment to distributing products, we ask how clinical trials can weather the COVID-19 pandemic.

Do pharma mergers and acquisitions improve R&D productivity and increase shareholder value?

How is the business of making medicine changing in light of the COVID-19 pandemic?

When developing countermeasures against COVID-19, resource-poor settings should not be forgotten.

It’s time to address the bottlenecks that lie in quality assurance review and release – and digital systems can help.

Why finding new talent is crucial to the success of the cell and gene therapy industry.

Experts from the UK discuss how the country is tackling the CGT skills gap.